Prognostic and Predictive Value of the 21-Gene Recurrence Score® for Women with Node-Positive Breast Cancer Receiving Chemotherapy
Slides from a journal article and transcribed comments from Joseph A Sparano, MD (1/20/10) at a closed roundtable meeting and a recent interview with Adam M Brufsky, MD, PhD (12/23/09)
Dr Brufsky is Associate Professor of Medicine and Associate Division Chief of Hematology/Oncology at the University of Pittsburgh, Co-Director of the Comprehensive Breast Cancer Center and Associate Director for Clinical Investigation at the University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania.
Dr Sparano is Professor of Medicine and Women’s Health at the Albert Einstein College of Medicine, Associate Chairman of the Department of Oncology at the Montefiore Medical Center and Director of the Breast Evaluation Center at the Montefiore-Einstein Cancer Center in Bronx, New York.
Presentation discussed in this issue:
Albain KS et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomized trial. Lancet Oncol 2010;11(1):55-65. Abstract
Go to previous Journal Club Go to next Journal Club